BEVIMI Launches at CG Well Summit with Focus on Cognitive Health
BEVIMI has launched at the inaugural CG Well Summit, announced in a press release. The company, founded by former leaders of Thorne HealthTech and Tempus, aims to advance cognitive longevity through AI-driven solutions and science-based nutritional products.
Co-Founder and President Joel Dudley, Ph.D., delivered the opening keynote, discussing the transition from sick care to true health care. BEVIMI's first product, slated for launch early next year, targets individuals at high risk of Alzheimer's disease. This product will undergo a clinical study to assess its safety and efficacy.
BEVIMI's approach involves a multi-ingredient system designed to address Alzheimer's biology pathways. The company plans to provide nutritional support, education, and AI-driven insights to combat cognitive decline, focusing on neuroinflammation and cognitive performance.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
INmune Bio and QCi Apply Quantum Computing to XPro Research
AbbVie Partners With Valkai on AI Tools for Clinical Development
Immorta Bio completes preclinical studies of AI designed senolytic peptide
Illumina Launches BioInsight Platform for Genomic Research
Veeva to Showcase Falcon and Vault AI at Boston Summit
Daily AI Brief: the AI news that matters, in your inbox.